Bailard Inc. lessened its position in shares of Kura Oncology (NASDAQ:KURA) by 11.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,000 shares of the company’s stock after selling 3,805 shares during the period. Bailard Inc. owned 0.09% of Kura Oncology worth $563,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in KURA. DekaBank Deutsche Girozentrale purchased a new position in Kura Oncology in the first quarter valued at about $226,000. Alps Advisors Inc. boosted its stake in shares of Kura Oncology by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 40,526 shares of the company’s stock valued at $760,000 after purchasing an additional 7,043 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Kura Oncology by 29.9% in the 1st quarter. Rhumbline Advisers now owns 18,095 shares of the company’s stock valued at $339,000 after purchasing an additional 4,160 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Kura Oncology by 69.3% in the 1st quarter. Wells Fargo & Company MN now owns 59,448 shares of the company’s stock valued at $1,115,000 after purchasing an additional 24,343 shares in the last quarter. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Kura Oncology in the 4th quarter valued at $155,000. 70.24% of the stock is owned by institutional investors and hedge funds.
Shares of Kura Oncology opened at $16.90 on Monday, Marketbeat.com reports. The company has a market cap of $563.68 million, a price-to-earnings ratio of -11.12 and a beta of 4.28. The company has a current ratio of 12.37, a quick ratio of 12.37 and a debt-to-equity ratio of 0.04. Kura Oncology has a 1-year low of $5.90 and a 1-year high of $24.02.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.11). equities research analysts predict that Kura Oncology will post -1.75 EPS for the current fiscal year.
KURA has been the subject of several analyst reports. Cann reissued a “buy” rating and set a $30.00 price target on shares of Kura Oncology in a research report on Friday, February 16th. BidaskClub raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 24th. Citigroup set a $28.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Friday, February 16th. Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, February 8th. Finally, ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Kura Oncology has an average rating of “Buy” and an average target price of $22.00.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.